We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+7.31%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$128M
AUM Growth
+$12.3M
Cap. Flow
+$10.9M
Cap. Flow %
8.47%
Top 10 Hldgs %
63.26%
Holding
34
New
7
Increased
9
Reduced
10
Closed
4

Top Buys

Rank Stock Value
1
HROW icon
Harrow
HROW
+$3.7M
2
PRTA icon
Prothena Corp
PRTA
+$3.05M
3
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$2.03M
4
GERN icon
Geron
GERN
+$2.02M
5
RARE icon
Ultragenyx Pharmaceutical
RARE
+$2.01M

Top Sells

Rank Stock Value
1
TVTX icon
Travere Therapeutics
TVTX
+$2.55M
2
MZOR
Mazor Robotics Ltd.
MZOR
+$2.11M
3
SCTL
Societal CDMO, Inc. Common Stock
SCTL
+$1.76M
4
PCYC
PHARMACYCLICS INC
PCYC
+$1.71M
5
KPTI icon
Karyopharm Therapeutics
KPTI
+$1.4M

Sector Composition

Rank Sector Weight
1 Healthcare 86.66%
2 Miscellaneous 13.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EVOK
26
DELISTED
Evoke Pharma
EVOK
$1.47M 1.14%
1,854
+170
+10% +$164K
ISEE
27
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$1.36M 1.06%
+35,000
New +$1.37M
CPXX
28
DELISTED
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
$1.02M 0.8%
405,000
+66,598
+20% +$182K
BLRX
29
BioLineRX
BLRX
$12.1M
$755K 0.59%
817
-266
-25% -$286K
KIPS
30
DELISTED
KIPS BAY MEDICAL INC
KIPS
$8.51K 0.01%
50,000
-722,031
-94% -$313K
KPTI icon
31
Karyopharm Therapeutics
KPTI
$44M
– –
-2,000
Closed -$1.4M
SCTL
32
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
– –
-245,300
Closed -$1.76M
MZOR
33
DELISTED
Mazor Robotics Ltd.
MZOR
– –
-120,000
Closed -$2.11M
KBIO
34
DELISTED
KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE)
KBIO
– –
-40,000
Closed -$730K
1
2

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q3 2014 Portfolio in Review

As of Q3 2014, Opaleye Management held 34 positions worth $128M, up 11% from $116M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Opaleye Management deployed $10.9M of net new capital in Q3 2014, opening 7 new positions and adding to 9 existing holdings. Its largest new stake was Harrow: 502,500 shares worth $3.73M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 83% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Travere Therapeutics, an estimated $2.55M trimmed.

  • Opaleye Management's largest Q3 2014 buy was Harrow: 502,500 shares worth $3.73M.
  • Opaleye Management added most to Prothena Corp in Q3 2014, an estimated $3.05M increase.
  • Opaleye Management's biggest Q3 2014 reduction was Travere Therapeutics, cutting an estimated $2.55M.
  • Opaleye Management fully exited Mazor Robotics Ltd. in Q3 2014, selling an estimated $2.11M.
  • Opaleye Management's ten largest holdings make up 63% of its $128M portfolio in Q3 2014.
  • Opaleye Management opened 7 new positions and closed 4 in Q3 2014.
  • Opaleye Management's portfolio value rose 11% quarter-over-quarter to $128M.

Based on Opaleye Management's 13F filing for Q3 2014, filed 14 Nov 2014.